Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein.
about
Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic miceUbiquitous expression of the rtTA2S-M2 inducible system in transgenic mice driven by the human hnRNPA2B1/CBX3 CpG island.Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis.Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes.Low cholesteryl ester transfer protein and phospholipid transfer protein activities are the factors making tree shrew and beijing duck resistant to atherosclerosisIdentification and characterization of dual inhibitors for phospholipid transfer protein and microsomal triglyceride transfer protein.An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux.Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study.Liver-specific phospholipid transfer protein deficiency reduces high-density lipoprotein and non-high-density lipoprotein production in mice.Adipocyte phospholipid transfer protein and lipoprotein metabolism.Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography.Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease.Linkage and association of phospholipid transfer protein activity to LASS4Phospholipid transfer protein plays a major role in the initiation of apolipoprotein B-containing lipoprotein assembly in mouse primary hepatocytes.Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.Functional expression of endothelial nitric oxide synthase fused to green fluorescent protein in transgenic mice.Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease.Reverse cholesterol transport and cholesterol efflux in atherosclerosis.Genetics and molecular biology: phospholipid transfer protein in atherogenesis.Genetic variation in phospholipid transfer protein modulates lipoprotein profiles in hyperalphalipoproteinemia.Serum CETP and PLTP activity in middle-aged men living in urban or rural area of the Lower Silesia region. PURE Poland sub-study.PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene studyPlasma PLTP activity is inversely associated with HDL-C levels.The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism.Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells.Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells.The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis.Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells.Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma.Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins.Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants.Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia.Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in Type 1 diabetes mellitus.Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice.Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency.Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice.Phospholipid transfer protein: its impact on lipoprotein homeostasis and atheroslcerosis.FoxO transcription factors are required for hepatic HDL-cholesterol clearance.Prodomain of Furin Promotes Phospholipid Transfer Protein Proteasomal Degradation in Hepatocytes.
P2860
Q24530027-8951041E-4029-4BF6-B8BF-51D68AE01E59Q33300595-463F9BBF-5A83-452B-BB44-ACAFFA9FAF2FQ33338480-B232F41D-CD99-4A8E-985E-012C22CF173FQ33714941-84ACF966-2A1E-4073-903B-DECCE15BBA11Q34244120-FD43A081-D114-4302-BC7E-8EE1EEA082A4Q34359986-13D8773D-42D1-4C89-9B00-F51A6622851DQ34655812-FC9AA027-5B7D-4C90-ACBD-A9B3F93270BCQ34656954-93B9A01C-A176-4B74-9981-7625DE97F8CFQ34680124-8985EB2F-5479-4D31-991F-4E0A00180F06Q35007458-F273FB73-979C-4F79-B733-26A8CCBC1050Q35153861-3B1FA162-A527-4D1C-ABF2-09BB33AB4125Q35181198-4FAE3252-FBEC-41F6-9547-15B2E32C0762Q35212888-EEADBDBE-368D-4EF7-A1B3-4CF5B08B09CFQ35221537-28042533-334B-410C-83B2-9ABF7CCFB283Q35341853-3F7F75A0-D0DD-4854-95B9-60A439C73450Q35792234-F7F99F48-8AB5-45F1-A7D9-DFDF7B5632E3Q36037988-FF2D284A-72CF-4368-BBC7-CAC738B2E672Q36300834-ACE274A4-164B-45A7-B1C8-EE9B7D839BF5Q36649583-9B77C41A-DE5E-45F6-93F7-F2450D7C0E18Q37040733-6653706D-1837-4214-86E0-A89F610E2E69Q37100511-856A5523-8B7E-484B-9E54-025CC19DB3EFQ37130814-962D5D11-FF64-40D6-AE4C-59DB7F31AD20Q37475203-5EE9B0AC-972E-4B44-8C2A-FFC662043133Q38035073-670D4276-5CE6-4A44-B0D6-6236B5839C18Q40625989-98CC8195-DF40-4CCB-8C39-8762BE2F62E8Q40650127-500E070D-F392-45E6-9D2C-4A5966405154Q41867827-DCBD92A2-3EEC-41B9-8B19-D5BCA5E58DDFQ44280956-33E9F698-1330-4030-97A7-26044C148822Q44445906-F1192DB8-6C49-4DD7-BB99-511607903577Q44480863-0D0B1B3D-E3E1-4DE2-9046-D729E866E76CQ44782031-03C51C7F-2018-475B-9778-7AA30C197CF6Q45285259-135BB1BB-A78C-4C70-AC17-7459306EF897Q46418500-C8A246F1-DF4F-45B4-9C2B-FB3DD6AE7652Q46504554-8D047109-ECBD-4067-AB2B-600A8AE4CF6AQ46806178-19C29C59-1BAB-4880-B78C-1796FE659C81Q46956583-5F34FF0E-BCC6-4537-9B7C-5ED8A179E4A4Q49167870-D7FCE502-B6C1-477B-9033-6A58F57BC479Q50036926-A99384D6-1159-4180-8750-48BBD397CBC4Q50163221-C6B3A30A-419E-45D2-8A62-142D764C1CD8Q52313438-7417A332-4895-4B66-B3C9-9667EDCC16C0
P2860
Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Increased risk of atherosclero ...... phospholipid transfer protein.
@en
Increased risk of atherosclero ...... phospholipid transfer protein.
@nl
type
label
Increased risk of atherosclero ...... phospholipid transfer protein.
@en
Increased risk of atherosclero ...... phospholipid transfer protein.
@nl
prefLabel
Increased risk of atherosclero ...... phospholipid transfer protein.
@en
Increased risk of atherosclero ...... phospholipid transfer protein.
@nl
P2093
P2860
P356
P1476
Increased risk of atherosclero ...... phospholipid transfer protein.
@en
P2093
Arie van Tol
Arthur van der Kamp
Frank Grosveld
Leo Scheek
Pim Visser
Rien van Haperen
Rini de Crom
Teus van Gent
P2860
P304
48938-48943
P356
10.1074/JBC.M209128200
P407
P577
2002-10-07T00:00:00Z